FY2025 EPS Estimates for HRMY Decreased by Cantor Fitzgerald

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of Harmony Biosciences in a note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn $2.43 per share for the year, down from their previous estimate of $3.27. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

A number of other analysts have also weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 target price on the stock. HC Wainwright reduced their target price on Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Mizuho reduced their target price on Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating on the stock in a research note on Thursday, February 20th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $53.11.

Harmony Biosciences Stock Performance

HRMY stock opened at $33.85 on Friday. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The business’s fifty day simple moving average is $36.64 and its two-hundred day simple moving average is $35.79. Harmony Biosciences has a twelve month low of $28.14 and a twelve month high of $41.61. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of 16.04, a PEG ratio of 0.47 and a beta of 0.80.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. During the same quarter in the prior year, the firm posted $0.45 EPS. Harmony Biosciences’s quarterly revenue was up 19.5% compared to the same quarter last year.

Institutional Investors Weigh In On Harmony Biosciences

A number of institutional investors have recently added to or reduced their stakes in HRMY. Creative Planning bought a new stake in Harmony Biosciences during the third quarter valued at about $246,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Harmony Biosciences by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock valued at $80,000 after purchasing an additional 360 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Harmony Biosciences by 8,867.7% in the third quarter. Nisa Investment Advisors LLC now owns 5,560 shares of the company’s stock valued at $222,000 after buying an additional 5,498 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Harmony Biosciences by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,931 shares of the company’s stock valued at $437,000 after buying an additional 4,259 shares during the last quarter. Finally, CWA Asset Management Group LLC purchased a new stake in Harmony Biosciences in the third quarter valued at about $576,000. Institutional investors own 86.23% of the company’s stock.

Insider Transactions at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 1,629 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $38.02, for a total transaction of $61,934.58. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Sandip Kapadia sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total value of $1,004,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,452 shares of company stock valued at $2,831,679. 30.80% of the stock is currently owned by corporate insiders.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.